
    
      This study will evaluate the potential to reduce nephrotoxic calcineurin inhibitors (CNI)
      therapy by lowering tacrolimus exposure from Advagraf® in combination with the
      non-nephrotoxic immunosuppressant sirolimus to avoid the risk of acute graft rejection,
      compared with an Advagraf® and Mycophenolate Mofetil (MMF) immunosuppressive regimen.
    
  